Chimeric Antigen Receptor News and Research

RSS

Remote controlling of CAR-T cells with heat to precisely target tumors

A team of researchers led by bioengineers at the Georgia Institute of Technology is expanding the precision and ability of a revolutionary immunotherapy that is already transforming oncology. CAR T-Cell therapy has been hailed by patients, clinical-researchers, investors, and the media as a viable cure for some cancers.

18 Aug 2021

Study identifies mechanism of resistance and presents a much-needed target for advanced leukemias

Too many "exhausted" T cells left in the wake of aggressive chemotherapy regimens for patients with advanced chronic lymphocytic leukemia (CLL) make it more challenging for chimeric antigen receptor (CAR) T cell therapy to do its job.

16 Aug 2021

Immunotherapy pairs ultrasound with immune cells to destroy tumors without toxic side effects

Bioengineers at the University of California San Diego have developed a cancer immunotherapy that pairs ultrasound with cancer-killing immune cells to destroy malignant tumors while sparing normal tissue.

12 Aug 2021

Magnetic nanoparticles could enhance the efficacy of cancer immunotherapy

Boosting the function of natural killer cells with magnetic nanoparticles could make cancer immunotherapy more efficient.

6 Aug 2021

Metabolites of intestinal bacteria can positively influence the efficacy of tumor therapies

Certain metabolites of bacteria from the intestine make immune cells more aggressive as a new study conducted by scientists from Würzburg and Marburg reveals. The findings could help improve cancer therapies.

9 Jul 2021

Promising immunotherapy uses cancer-killing cells to destroy malignant tumors

Researchers at McMaster University have developed a promising new cancer immunotherapy that uses cancer-killing cells genetically engineered outside the body to find and destroy malignant tumors.

28 Jun 2021

Mayo Clinic researchers are working toward new CAR-T cell treatment for multiple myeloma

Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma.

25 Jun 2021

Different comorbid conditions in COVID-19 patients can impact outcomes of positive PCR test results

New study results indicate that different comorbid conditions affecting individuals diagnosed with COVID-19 may impact how long they continue to receive positive SARS-CoV-2 polymerase chain reaction (PCR) test results.

17 Jun 2021

UC San Diego Health offers new immunotherapy treatment for multiple myeloma following FDA approval

Following the Food and Drug Administration's approval, UC San Diego Health is the first designated medical center in San Diego certified to offer a new immunotherapy treatment of multiple myeloma outside of a clinical trial.

3 Jun 2021

Moffitt Cancer Center presents new data from dozens of clinical research studies at ASCO

Moffitt Cancer Center, a national leader in cancer care and research and the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, is presenting new data from dozens of clinical research studies at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, the world's largest clinical cancer research meeting.

1 Jun 2021

Novel approach to immunotherapy design could pave the way for new brain cancer treatments

A novel approach to immunotherapy design could pave the way for new treatments for people with an aggressive form of brain cancer called glioblastoma.

10 May 2021

Arresting tumor growth for a variety of cancers through T cell engineering

Through T cell engineering, researchers at Virginia Commonwealth University Massey Cancer Center show that it's possible to arrest tumor growth for a variety of cancers and squash the spread of cancer to other tissues.

30 Apr 2021

Researchers receive $3.75 million to study the impact of fluid flow on CAR-T cell therapy for brain cancer

Glioblastoma multiforme is among the most lethal of cancers and the most stubborn in the face of treatment. Fewer than 20 percent of patients survive more than two years after diagnosis, according to the Central Brain Tumor Registry of the United States.

29 Apr 2021

Stem cell transplants offer long-term benefits for pediatric cancer patients receiving immunotherapy

Children and young adults who receive CAR T-cell therapy for the most common childhood cancer - acute lymphoblastic leukemia - suffer remarkably fewer relapses and are far more likely to survive when the treatment is paired with a subsequent stem cell transplant, a new study finds.

1 Apr 2021

First cell-based gene therapy approved by the FDA for treating multiple myeloma

The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy.

29 Mar 2021

Moffitt researchers use mathematical modeling to help explain outcomes of CAR T-cell therapy

Chimeric antigen receptor T-cell therapy, or CAR T, is a relatively new type of therapy approved to treat several types of aggressive B cell leukemias and lymphomas.

25 Mar 2021

Study explores how CAR T immunotherapy could be used to treat solid tumors

A study recently published in the journal Science looked into how CAR T immunotherapy could be used to treat solid tumors in addition to leukemias. The programming of CAR T cells opens avenues for applying cell therapies to, for example, breast cancer or ovarian cancer in the future.

18 Mar 2021

CAR T-cell therapy triples expected length of remission for relapsed multiple myeloma patients

A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times, according to an international clinical trial with UT Southwestern as the lead enrolling site.

8 Mar 2021

Experimental safety switch reduces severity of CAR-T immunotherapy-related side effects

UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur.

4 Mar 2021

Innovative cancer treatment effective in combating fungal infection in vitro and in mice

An innovative cell-based treatment for cancer has been found promising for the control of infections caused by fungi.